Systemic lupus erythematosus secondary prevention: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{Systemic lupus erythematosus}} {{CMG}}; {{AE}} {{RT}} ==Overview== ===Prevention of complications during pregnancy=== While most infants born to mothers who have SLE are...")
 
 
(10 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
{{Systemic lupus erythematosus}}
{{Systemic lupus erythematosus}}


{{CMG}}; {{AE}} {{RT}}
{{CMG}}; {{AE}} {{MIR}}, {{RT}}


==Overview==
==Overview==
Secondary prevention strategies following systemic lupus erythematosus include using [[aspirin]], [[ACE inhibitor|ACE inhibitors]], and [[statins]] to reduce [[Atherosclerotic disease|atherosclerotic diseases]], and using [[Cancer screening|cancer screenings]].


===Prevention of complications during pregnancy===
==Secondary Prevention==
 
Aims of secondary prevention measures for SLE include:<ref name="pmid22593636">{{cite journal |vauthors=Maidhof W, Hilas O |title=Lupus: an overview of the disease and management options |journal=P T |volume=37 |issue=4 |pages=240–9 |date=April 2012 |pmid=22593636 |pmc=3351863 |doi= |url=}}</ref><ref name="pmid10782816">{{cite journal |vauthors=Zangger P, Gladman DD, Urowitz MB, Bogoch ER |title=Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus |journal=J. Rheumatol. |volume=27 |issue=4 |pages=919–23 |year=2000 |pmid=10782816 |doi= |url=}}</ref>
While most infants born to mothers who have SLE are healthy, pregnant mothers with SLE should remain under a doctor's care until delivery. Neonatal lupus is rare, but identification of mothers at highest risk for complications allows for prompt treatment before or after birth.  In addition, SLE can flare during pregnancy, and proper treatment can maintain the health of the mother longer. Women pregnant and known to have the antibodies for anti-Ro (SSA) or anti-La (SSB) should have echocardiograms during the 16th and 30th weeks of pregnancy to monitor the health of the heart and surrounding vasculature.
* Preventing [[glucocorticoid]] usage and using the minimum dosage to prevent [[osteonecrosis]] and [[Osteoporosis|osteoprosis]] side effects
 
* Decreasing [[Atherosclerosis|atherosclerotic]] events in patients
Even [[contraception]] was routinely advised in treating SLE patients, getting pregnant during active disease was eventually found. [[Lupus nephritis]] was the most common manifestation. Overall live-birth was 72.7%. Pregnancy lost was due to [[abortion]] and dead fetus in utero. Pregnancy outcome was worse in SLE patients who had disease flares up or emerging during pregnancy.<ref name="pmid19253790">{{cite journal |author=Foocharoen C, Nanagara R, Salang L, Suwannaroj S, Mahakkanukrauh A |title=Pregnancy and disease outcome in patients with systemic lupus erythematosus (SLE): a study at Srinagarind Hospital |journal=J Med Assoc Thai |volume=92 |issue=2 |pages=167–74 |year=2009 |month=February |pmid=19253790 |doi= |url= |issn=}}</ref>
** Low doses of [[aspirin]]
** [[ACE inhibitor|ACE inhibitors]]
** [[Statins]]
* For prevention and/or early diagnosis of [[malignancies]]:
** Regular age-related specific [[cancer screening]] recommended for the general population


==References==
==References==
{{reflist|2}}
{{reflist|2}}


 
[[Category:Arthritis]]
[[Category:Dermatology]]
[[Category:Diseases involving the fasciae]]
[[Category:Rheumatology]]
[[Category:Nephrology]]
[[Category:Autoimmune diseases]]
[[Category:Disease]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 13:41, 6 June 2018

Systemic lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Systemic lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Lupus and Quality of Life

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Systemic lupus erythematosus secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Systemic lupus erythematosus secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Systemic lupus erythematosus secondary prevention

on Systemic lupus erythematosus secondary prevention

Systemic lupus erythematosus secondary prevention in the news

Blogs onSystemic lupus erythematosus secondary prevention

Directions to Hospitals Treating Systemic lupus erythematosus

Risk calculators and risk factors for Systemic lupus erythematosus secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2], Raviteja Guddeti, M.B.B.S. [3]

Overview

Secondary prevention strategies following systemic lupus erythematosus include using aspirin, ACE inhibitors, and statins to reduce atherosclerotic diseases, and using cancer screenings.

Secondary Prevention

Aims of secondary prevention measures for SLE include:[1][2]

References

  1. Maidhof W, Hilas O (April 2012). "Lupus: an overview of the disease and management options". P T. 37 (4): 240–9. PMC 3351863. PMID 22593636.
  2. Zangger P, Gladman DD, Urowitz MB, Bogoch ER (2000). "Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus". J. Rheumatol. 27 (4): 919–23. PMID 10782816.

Template:WH Template:WS